CTLA4 and colorectal carcinoma: However, in the NICHE study (NCT03026140) (35), pMMR CRC patients who received neoadjuvant CTLA-4 inhibitor (ipilimumab) combined with PD-1 inhibitor (nivolumab) and celecoxib showed no significant improvement.